Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures turns negative
Q1 FY2026 capital expenditures was -$24.86K, compared with $3 a year earlier. Trailing-twelve-month capital expenditures was -$24.85K.
Context
- Capital expenditures increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near -$24.86K or moves back toward the trailing-twelve-month quarterly average of -$6.21K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- +100.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | +100.0% |
| FY2024 | 2024-12-31 | (4) | — |
| FY2023 | 2023-12-31 | 0 | +100.0% |
| FY2022 | 2022-12-31 | (3) | — |
| FY2021 | 2021-12-31 | 0 | — |
Capital Expenditures vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's LTM Mar 2026 capital expenditures of $24.85K is the smallest of the 2 companies compared; the peer median is $223.31K.
- Its year-over-year change of +1242500.0% is the highest of 2, against a peer median of +71.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $223.31K | +71.4% | +1.9% | — | |
| LTM Mar 2026 | $24.85K | +1242500.0% | — | — | |
| Peer median (excluding LIXT) | $223.31K | +71.4% | +1.9% | — | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.